Maricel M. Apuli's most recent trade in BridgeBio Pharma Inc was a trade of 14,170 Common Stock done . Disclosure was reported to the exchange on March 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2026 | 14,170 | 136,115 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 66.00 per share. | 26 Feb 2026 | 2,000 | 121,945 (0%) | 0% | 66 | 132,000 | Common Stock |
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.25 per share. | 16 Feb 2026 | 4,349 | 124,455 (0%) | 0% | 75.2 | 327,262 | Common Stock |
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 74.31 per share. | 16 Feb 2026 | 510 | 123,945 (0%) | 0% | 74.3 | 37,898 | Common Stock |
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.15 per share. | 12 Dec 2025 | 2,003 | 128,294 (0%) | 0% | 75.1 | 150,525 | Common Stock |
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 74.26 per share. | 08 Dec 2025 | 2,000 | 130,297 (0%) | 0% | 74.3 | 148,520 | Common Stock |
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.39 per share. | 16 Nov 2025 | 4,781 | 132,297 (0%) | 0% | 66.4 | 317,411 | Common Stock |
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.32 per share. | 16 Aug 2025 | 4,781 | 137,078 (0%) | 0% | 51.3 | 245,361 | Common Stock |
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 45.44 per share. | 07 Aug 2025 | 1,000 | 141,859 (0%) | 0% | 45.4 | 45,440 | Common Stock |
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.84 per share. | 16 May 2025 | 4,780 | 142,859 (0%) | 0% | 33.8 | 161,755 | Common Stock |
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 38.51 per share. | 02 May 2025 | 1,026 | 147,639 (0%) | 0% | 38.5 | 39,509 | Common Stock |
| BridgeBio Pharma Inc | Maricel M. Apuli | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2025 | 23,660 | 148,665 (0%) | 0% | 0 | Common Stock |